InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

InflaRx N.V. (IFRX) shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab) to treat adult patients with acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.Th ...